Here we used a rodent model of type 2 diabetes (UCD‐T2DM rats) to investigate whether GH supplementation could augment the anti‐diabetic effects of liraglutide (a GLP‐1 receptor agonist) treatment. Here, GH1 is linked to type 2 diabetes mellitus.